Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | ITGAV | P06756 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3268531 | 0.92 | ITGB3 (0.65) | MEN1KMT2AL3MBTL1ITGB3ITGA2B | |
| SCHEMBL7400070 | 0.92 | ITGB3 (0.65) | MEN1KMT2AL3MBTL1ITGB3ITGA2B | |
| SCHEMBL3266667 | 0.90 | MEN1 (0.60) | MEN1KMT2AL3MBTL1ITGB3ITGA2B | |
| Butane SCHEMBL27344498 | 0.83 | MEN1 (0.51) | MEN1KMT2AL3MBTL1ITGB3ITGA2B | |
| SCHEMBL286032 | 0.80 | MEN1 (0.63) | MEN1KMT2AL3MBTL1CA1CA2 | |
| SCHEMBL286031 | 0.80 | MEN1 (0.63) | MEN1KMT2AL3MBTL1CA1CA2 | |
| SCHEMBL6822184 | 0.80 | ITGB3 (0.63) | MEN1KMT2AL3MBTL1ITGB3ITGA2B | |
| SCHEMBL6032775 | 0.80 | ITGB3 (0.64) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL6822181 | 0.80 | ITGB3 (0.63) | MEN1KMT2AL3MBTL1ITGB3ITGA2B | |
| SCHEMBL8713012 | 0.80 | ITGB3 (0.67) | ITGB3ITGA2BCA2ACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0951295-B1 | COMPOSITIONS FOR USE IN INHIBITING OF ALPHA-V-BETA3 MEDIATED ANGIOGENESIS | SCRIPPS RESEARCH INST (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20060270710-A1 | Methods for inhibition of angiogenesis | THE SCRIPPS RESEARCH INSTITUTE | 2006-11-30 | — | — | US | disclosed |
| US-20060165703-A1 | Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-07-27 | — | — | US | disclosed |
| US-7053041-B1 | Methods and compositions useful for inhibition of αvβ5mediated angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1613268-A2 | METHODS FOR INHIBITION OF ANGIOGENESIS | The Scripps Research Institute (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087057-A2 | METHODS FOR INHIBITION OF ANGIOGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040063790-A1 | Methods for inhibition of angiogenesis | THE SCRIPPS RESEARCH INSTITUTE | 2004-04-01 | — | — | US | disclosed |
| US-20030176334-A1 | Methods and compositions useful for inhibition of angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2003-09-18 | — | — | US | disclosed |
| US-6500924-B1 | PACKAGE FOR USING ANTAGONISTS OF THE VITRONECTIN RECEPTOR ALPHA-V BETA3 COMPRISING A METALLOPROTEINASE POLYPEPTIDE OF GIVEN AMINO ACID SEQUENCE; TREATING ARTHRITIS, RHEUMATOID ARTHRITIS, RETINOPATHY AND TUMORS | THE SCRIPPS RESEARCH INSTITUTE | 2002-12-31 | — | — | US | disclosed |
| EP-0844874-A4 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ALPHA v BETA 5 MEDIATED ANGIOGENESIS | SCRIPPS RESEARCH INST (US) | 2001-02-14 | — | — | EP | disclosed |
| EP-0907661-A4 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF alpha v beta 5 MEDIATED ANGIOGENESIS | SCRIPPS RESEARCH INST (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0951295-A4 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ANGIOGENESIS | SCRIPPS RESEARCH INST (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0951295-A1 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ANGIOGENESIS | The Scripps Research Institute (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0907661-A1 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF alpha v beta 5 MEDIATED ANGIOGENESIS | The Scripps Research Institute (US) | 1999-04-14 | — | — | EP | disclosed |
| EP-0844874-A1 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF $g(a) v?$g(b) 5? MEDIATED ANGIOGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-06-03 | — | — | EP | disclosed |
| WO-1997045447-A9 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS | — | 1998-03-12 | — | — | WO | disclosed |
| WO-1997045137-A1 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ANGIOGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-12-04 | — | — | WO | disclosed |
| WO-1997045447-A1 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-12-04 | — | — | WO | disclosed |
| WO-1997006791-A9 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS | — | 1997-04-03 | — | — | WO | disclosed |
| WO-1997006791-A1 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063790-A1 | Methods for inhibition of angiogenesis | FLT4, ANXA3, VCAM1 | MEN1 3603/4885KMT2A 4513/4885L3MBTL1 819/4885 |
| US-20030176334-A1 | Methods and compositions useful for inhibition of angiogenesis | VCAM1, FLT4, TEK | MEN1 2778/4885KMT2A 4744/4885L3MBTL1 3766/4885 |
| US-20060165703-A1 | Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis | ITGA5, ITGB5, ITGAV | MEN1 2650/4885KMT2A 4741/4885L3MBTL1 4752/4885 |
| US-20060270710-A1 | Methods for inhibition of angiogenesis | FLT4, KDR, FLT1 | MEN1 3700/4885KMT2A 4186/4885L3MBTL1 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.